top of page

Cardiovascular

Health

CardioMetabolic 

Health

Lung Health

Bone Health

All-in-one AI-CVD

497e6f54-782b-4e077a-3a7144e4f3e4.png

AutoFracture

(coming soon)

upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
upscaled_5x.png
0bdba309-a76a-4215-b207-90a7932bb681.png
iScreen Shoter - 20260520111737117 1.png
Frame 1000004271.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520105243724 1.png
iScreen Shoter - 20260520100645073 1.png

1 Non-Contrast Scan              10+ Actionable Reports

Mount Sinai Radiologist Presents New AutoBMD AI Data at I-ELCAP Showing High Rates of Previously Undetected Osteoporosis

  • Oct 9, 2025
  • 2 min read

FOR IMMEDIATE RELEASE

New York, NY — October 9, 2025


New findings from Mount Sinai Hospital demonstrate hat AutoBMD™ AI can identify large numbers of patients with previously undiagnosed osteoporosis and low bone density on routine chest CT scans performed for lung cancer screening. The data were presented today by Mingqian Huang, MD (Icahn School of Medicine at Mount Sinai) at the I-ELCAP 48th International Conference on Screening for Lung Cancer in New York City. Dr. Huang’s profile: https://profiles.mountsinai.org/mingqian-huang Mount Sinai Health System


“Opportunistic screening from existing CT scans can close critical gaps in osteoporosis detection,” said Dr. Morteza Naghavi, President of HeartLung AI, the provider of AutoBMD AI. “By leveraging AutoBMD AI on scans already acquired for heart and lung studies, health systems can surface clinically significant bone loss earlier—without added scan time, cost, or radiation—so patients at risk are not missed.”



About the study

Using AutoBMD AI to analyze standard low-dose chest CTs, investigators observed a substantial prevalence of patients meeting thresholds consistent with osteoporosis or osteopenia who had no prior diagnosis on record. The results underscore the value of integrating bone health assessment into comprehensive CT-based screening programs to enable earlier intervention, fracture prevention, and improved outcomes. (Detailed statistics and methodology available upon request.)


About AutoBMD™ AI

HeartLung's AutoBMD™ is an AI-powered, cloud-based solution for opportunistic bone mineral density measurement using existing CT scans. It is the only DEXA-equivalent, CT-based osteoporosis screening approved by the FDA, applicable to over 25 million CT scans annually and reimbursed by Medicare.


Conference

I-ELCAP 48th International Conference on Screening for Lung Cancer (& 16th Conference on Research for Early Lung Cancer Treatment)October 9–11, 2025 — Goldwurm Auditorium, Icahn School of Medicine at Mount Sinai



Comments


Ready to Unlock the Value in Your CT Scans?

Join leading healthcare providers using AI-CVD to save lives and increase revenue, and lead the future of preventive cardiology.

  • Twitter
  • LinkedIn
  • Facebook
  • Instagram
  • Youtube

2450 Holcombe Blvd
TMC Innovations
Houston, TX 77021

aicvd patent_edited_edited.jpg
ISO LOGO_edited.png

©2026 HeartLung Corporation. All Rights Reserved. US Patent Nos US9119590*, US10695022, US11610686, US18167691, US20240115224, and Patents Pending. AI-CVD, AI-CAC, AutoBMD, AutoCAC, AutoChamber and other trademarks shown on this website are protected under intellectual property rights of HeartLung Corporation in the United States.

bottom of page